1. A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine‐Rich Repeat Kinase 2 Mutation. Issue 2 (12th June 2021) Authors: Ahamadi, Malidi; Mehrotra, Nitin; Hanan, Nathan; Lai Yee, Ka; Gheyas, Ferdous; Anton, Judith; Bani, Massimo; Boroojerdi, Babak; Smit, Hans; Weidemann, Jonas; Macha, Sreeraj; Thuillier, Vincent; Chen, Chao; Yang, Minhua; Williams‐Gray, Caroline H.; Stebbins, Glenn T.; Pagano, Gennaro; Hang, Yaming... Journal: Clinical pharmacology & therapeutics Issue: Volume 110:Issue 2(2021) Page Start: 508 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers. (June 2015) Authors: Chen, Lin-Zhi; Jungnik, Arvid; Mao, Yanping; Philip, Elsy; Sharp, Dale; Unseld, Anna; Seman, Leo; Woerle, Hans-Jürgen; Macha, Sreeraj Journal: Xenobiotica Issue: Volume 45:Number 6(2015:Jun.) Page Start: 520 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data. Issue 4 (11th March 2020) Authors: Conrado, Daniela J.; Duvvuri, Sridhar; Geerts, Hugo; Burton, Jackson; Biesdorf, Carla; Ahamadi, Malidi; Macha, Sreeraj; Hather, Gregory; Francisco Morales, Juan; Podichetty, Jagdeep; Nicholas, Timothy; Stephenson, Diane; Trame, Mirjam; Romero, Klaus; Corrigan, Brian Journal: Clinical pharmacology & therapeutics Issue: Volume 107:Issue 4(2020) Page Start: 796 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Development of a Disease Progression Model for Leucine‐Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs. Issue 3 (5th December 2019) Authors: Ahamadi, Malidi; Conrado, Daniela J; Macha, Sreeraj; Sinha, Vikram; Stone, Julie; Burton, Jackson; Nicholas, Timothy; Gallagher, Jill; Dexter, David; Bani, Massimo; Boroojerdi, Babak; Smit, Hans; Weidemann, Jonas; Chen, Chao; Yang, Minhua; Maciuca, Romeo; Lawson, Rachael; Burn, David; Marek, Kenn... Journal: Clinical pharmacology & therapeutics Issue: Volume 107:Issue 3(2020) Page Start: 553 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis. Issue 1 (27th July 2017) Authors: Conrado, Daniela J.; Nicholas, Timothy; Tsai, Kuenhi; Macha, Sreeraj; Sinha, Vikram; Stone, Julie; Corrigan, Brian; Bani, Massimo; Muglia, Pierandrea; Watson, Ian A.; Kern, Volker D.; Sheveleva, Elena; Marek, Kenneth; Stephenson, Diane T.; Romero, Klaus Journal: Clinical and translational science Issue: Volume 11:Issue 1(2018) Page Start: 63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Drug‐Drug Interaction of Letermovir and Atorvastatin in Healthy Participants. Issue 4 (14th February 2022) Authors: McCrea, Jacqueline B.; Menzel, Karsten; Adedoyin, Adedayo; Cho, Carolyn R.; Fox‐Bosetti, Sabrina; Macha, Sreeraj; Zhao, Tian; Liu, Fang; Panebianco, Deborah; Stoch, S. Aubrey; Iwamoto, Marian Journal: Clinical pharmacology in drug development Issue: Volume 11:Issue 4(2022) Page Start: 420 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects. Issue 2 (27th March 2013) Authors: Seman, Leo; Macha, Sreeraj; Nehmiz, Gerhard; Simons, Gudrun; Ren, Bailuo; Pinnetti, Sabine; Woerle, Hans J.; Dugi, Klaus Journal: Clinical pharmacology in drug development Issue: Volume 2:Issue 2(2013:Apr.) Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Exposure–Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients. Issue 2 (29th November 2021) Authors: Prohn, Marita; Cho, Carolyn R.; Viberg, Anders; Dykstra, Kevin; Davis, Casey; Sabato, Philip; Stone, Julie; Badshah, Cyrus; Murata, Yoshihiko; Leavitt, Randi; Fancourt, Craig; Macha, Sreeraj Journal: Clinical pharmacology & therapeutics Issue: Volume 111:Issue 2(2022) Page Start: 485 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes. (December 2014) Authors: Riggs, Matthew M.; Seman, Leo J.; Staab, Alexander; MacGregor, Thomas R.; Gillespie, William; Gastonguay, Marc R.; Woerle, Hans J.; Macha, Sreeraj Journal: British journal of clinical pharmacology Issue: Volume 78:Number 6(2014:Dec.) Page Start: 1407 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Lack of pharmacokinetic interaction between single oral doses of letermovir (MK-8228) and fluconazole in healthy subjects. Issue 1 (January 2019) Authors: Adedoyin, Adedayo; Fox-Bosetti, Sabrina; Fancourt, Craig; Liu, Fang; Menzel, Karsten; Zhao, Tian; Auger, Patrice; Mirzac, Angela; Tomek, Charles; Panebianco, Deborah; Macha, Sreeraj; McCrea, Jacqueline; Iwamoto, Marian Journal: Drug metabolism and pharmacokinetics Issue: Volume 34:Issue 1(2019)Supplement Page Start: S39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗